可授權技術分類
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||
|
||||||||||
 市場需求 / Market Needs： |
||||||||||
| 2014年爆發的新型H5N8 (H5 clade 2.3.4.4) 禽流感病毒是高病原性禽流感病毒（highly pathogenic avian influenza virus, HPAIV）的一個亞型，該病毒對野生鳥類和家禽有很強的殺傷力，養殖場若爆發H5N8或相關之H5Nx亞型的禽流感疫情，往往必須立即進行全場撲殺，和相應的疫病管控作為，造成很大的農業經濟損失。H5N8一度被認為與人類無關，但是2021年2月俄羅斯報告有7人感染此病毒，為全球首次出現人感染H5N8的案例。H5Nx之禽流感已造成全球之高度重視，世界動物衛生組織OEI及世界衛生組織WHO亦已發布警示。 The H5N8 avian influenza virus (AIV) that emerged in 2014 is a subtype of highly pathogenic avian influenza virus (HPAIV). H5N8 HPAIV (H5 clade 2.3.4.4) has a strong lethality to wild birds and poultry. Related H5Nx AIV epidemics often have to be culled immediately on the whole farm sites, and corresponding disease control has caused great agricultural economic losses. H5N8 was once considered to have no further concern with humans, but in February 2021, Russia reported 7 people infected with the virus, which is the first case of human infection with H5N8 in the world. The World Organisation for Animal Health (OIE) and the World Health Organization (WHO) have also issued warnings and the H5Nx AIV has caused global attention. |
||||||||||
| 技術摘要 / Our Technology： |
||||||||||
| 單株抗體7H6C對H5N8、H5N1、H5N6、H5N3及H5N2之血球凝集素 (Hemagglutinin, HA) 具有極高之專一性，且7H6C之抗原結合位已被鑑定出來，位於H5N8 HA之Valine-88至Aspartate-112之間。實驗結果顯示7H6C具有很高之H5病毒亞型特異性，並且不會結合H1N1、H3N2與H7N9之HA。7H6C可應用於西方墨點法、酵素連結免疫分析法、細胞染色、免疫化學染色等生化分析技術。 Monoclonal antibody 7H6C is highly specific to the hemagglutinins (HAs) of H5N8, H5N1, H5N6, H5N3 and H5N2 AIVs. The antigenic binding epitope of 7H6C is located in the region of valine-88 to aspartate-112 of H5N8 HA. Experimental results show that 7H6C exhibits H5-subtype specificity and does not bind to the HAs of H1N1, H3N2 and H7N9. 7H6C can be applied to biochemical analysis techniques such as Western blotting, enzyme-linked immunosorbent assay, cell staining, and immunohistochemistry staining. |
||||||||||
| 優勢 / Strength： |
||||||||||
| 1.單株抗體7H6C對H5N8及H5Nx亞型禽流感病毒之HA具有極高之專一性。 2.7H6C不會結合H1N1、H3N2與H7N9之HA。 1. Monoclonal antibody 7H6C exhibits high specificity to HA of H5N8 and H5Nx-subtype AIVs. 2. 7H6C will not bind to the HAs of H1N1, H3N2 and H7N9 influenza viruses. |
||||||||||
| 競爭產品 / Competing Products： |
||||||||||
| 本發明為自行研發之單株抗體，其結合於H5N8等H5Nx亞型禽流感病毒之HA之Epitope具特異性，市場上無相同之產品。 The present mAb 7H6C hybridoma cell line was developed in the laboratory at NTU. The unique antigenic epitope recognized by 7H6C has not been revealed elsewhere. |
||||||||||
| 專利簡述 / Intellectual Properties： |
||||||||||
| 1.單株抗體7H6C之文獻請參見：Cheng YC, Chang SC* (2021). Appl Microbiol Biotechnol. 105(1):235-245. 2.單株抗體7H6C之細胞株尚未申請專利。 1. The technical data about the 7H6C hybridoma cell line can be seen in the published paper: Cheng YC, Chang SC* (2021). Appl Microbiol Biotechnol. 105(1):235-245. 2. The 7H6C hybridoma cell line has not submitted for patent application. |
||||||||||
| 聯繫方式 / Contact： |
||||||||||
|
||||||||||
 |
||||||||||
